Please use this identifier to cite or link to this item:
|Title:||Contribution of the GSTP1 c.313A > G variant to hearing loss risk in patients exposed to platin chemotherapy during childhood|
|Author:||Liberman, P. H. P.|
Goffi-Gomez, M. V. S.
Jacob, P. L.
de Paula, C. A. A.
Sartorato, E. L.
Torrezan, G. T.
Ferreira, E. N.
Carraro, D. M.
|Abstract:||Ototoxicity is a potential adverse effect of chemotherapy with platin drugs, such as cisplatin and carboplatin, in children. Hearing loss (HL) affecting frequencies below 4kHz can compromise speech perception. The aim of this study was to investigate whether genetic variants previously implicated in ototoxicity are associated with HL overall and HL below 4kHz in pediatric oncology patients treated with cisplatin or carboplatin.Materials and methodsPatients given cisplatin or carboplatin for a pediatric cancer at least 5years prior to the start of the study were enrolled. The patients underwent comprehensive audiological evaluations and genotyping to detect the presence of the GJB2 c.35delG, GSTP1 c.313A>G, and MT-RNR1m.1555A>G polymorphisms.ResultsHL was identified in 31/61 patients (50.8%), including 28/42 treated with cisplatin (66.6%) and 3/19 treated with carboplatin (15.8%). HL was associated with higher mean doses of cisplatin (p=.002) and carboplatin (p=.010). The c.313A>G variant of GSTP1 (heterozygous or homozygous) was detected in 31/61 patients (50.8%). An association between this variant allele and HL involving frequencies 4kHz was identified (p=.020; 10-fold vs. non-carriers). No associations with HL were observed for GJB2 or MT-RNR1 gene variants.ConclusionThe GSTP1 c.313A>G variant may increase the risk of low-frequency HL in pediatric oncology patients treated with cisplatin or carboplatin chemotherapy|
|Appears in Collections:||CBMEG - Artigos e Outros Documentos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.